Huber B1, Schmid G2.
Epilepsy Behav. 2016 Dec 27;66:74-79. doi: 10.1016/j.yebeh.2016.10.020. [Epub ahead of print]PURPOSE: The objective of this work was to review systematically the efficacy and tolerability of perampanel (PER) in residential patients of an epilepsy center.METHOD: We adopted an industry-independent noninterventional retrospective evaluation on the basis of the paper and electronic records complemented by personal information on the part of the treating neurologists. All patients (N=26, 15 females, mean age: 30, range 21-55years) started on PER from its introduction to the market in September 2012 until December 15th 2013 were included. Read More